D. D. Richman

发表

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence

D. Richman, L. Bacheler, H. Günthard, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

J. Corbeil, D. Richman, D. Havlir, 1994, Journal of virology.

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.

T. Greenough, D. Havlir, S. Spector, 1995, The Journal of infectious diseases.

Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

T. Greenough, D. Havlir, S. Spector, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

M. Hirsch, D. Richman, C. Petropoulos, 2000, JAMA.

In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues

D. Richman, D. Havlir, J. Wong, 1997, Journal of virology.

A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team.

C. Pettinelli, Stephen A. Spector, Paul S. Lietman, 1995, The Journal of infectious diseases.

The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes

D. D. Richman, C A Spina, T J Kwoh, 1994, The Journal of experimental medicine.

Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections

D. Richman, P. Klenerman, S. Rowland-Jones, 2002, Nature Medicine.

Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy

Alan S. Perelson, Douglas D. Richman, Simon D. W. Frost, 1999, Journal of Virology.

The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.

A. Trkola, D. Richman, J. Moore, 2000, The Journal of infectious diseases.

Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression

M. Hirsch, D. Richman, D. Havlir, 2001, AIDS.

A pilot study of low-dose zidovudine in human immunodeficiency virus infection.

D. Richman, C. Pettinelli, S. Spector, 1990, The New England journal of medicine.

Estimating selection pressures on HIV‐1 using phylogenetic likelihood models

Sergei L. Kosakovsky Pond, D. Richman, S. Little, 2008, Statistics in medicine.

Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene

D. Richman, C. Spina, J. Guatelli, 1994, Journal of virology.

Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial.

G. Badger, D. Richman, L. Corey, 1984, JAMA.

Community HIV‐1 drug resistance is associated with transmitted drug resistance

G. Osorio, Myres W. Tilghman, W. Christopher Mathews, 2014, HIV medicine.

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.

D. Richman, D. Havlir, J. Mellors, 1998, JAMA.

Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein

D. Richman, C. Spina, M. Pandori, 1996, Journal of Virology.

Viral HIV-1

S. Little, C. Spina, D. Havlir, 1999 .

Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.

D. Richman, D. D. Richman, 1990, The American journal of medicine.

Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection.

D. Richman, J. Andrews, D. D. Richman, 1988, The American journal of medicine.

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

R. Schooley, R. Haubrich, D. Richman, 1999, AIDS.

Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine.

R. Chaisson, D. Richman, C. Flexner, 1991, JAMA.